DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
前收盤價
US$179.25
+US$2.23 · +1.26%
盤中時間採用ET。市場資料可能有所延遲。
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
日內區間
目前US$179.25
52週區間
目前US$179.25
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
54
合理估值
情緒
60
多空交錯
風險
20
低風險
動能
72
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
日內區間
目前US$179.25
52週區間
目前US$179.25
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 136.43億 USD | 128.16億 USD | 121.4億 USD | 116.1億 USD | 116.19億 USD |
| 銷貨成本 | 99.59億 USD | 85.99億 USD | 83.2億 USD | 82.1億 USD | 79.72億 USD |
| 毛利 | 36.84億 USD | 42.17億 USD | 38.2億 USD | 34億 USD | 36.46億 USD |
| 銷售、一般及管理費用 | 16.74億 USD | 15.38億 USD | 14.74億 USD | 13.55億 USD | 11.95億 USD |
| 營業費用 | 16.74億 USD | 21.27億 USD | 22.18億 USD | 20.61億 USD | 18.49億 USD |
| 利息支出 | 5.5億 USD | 4.7億 USD | 3.99億 USD | 3.57億 USD | 2.85億 USD |
| 折舊和攤銷 | 7.15億 USD | 7.24億 USD | 7.45億 USD | 7.33億 USD | 6.81億 USD |
| 營業利益 | 20.11億 USD | 20.9億 USD | 16.03億 USD | 13.39億 USD | 17.97億 USD |
| 淨利 | 7.47億 USD | 9.36億 USD | 6.92億 USD | 5.6億 USD | 9.78億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T115.73億0.01%129.35兆 JPY0.09%¥122,850+0.12%
Invesco S&P 500 Equal Weight ETFRSP1.92億0.20%977.83億 USD0.20%US$213.04+0.55%
Vanguard Morningstar Total Stock Market ETFVTI1.8億0.01%2.3兆 USD0.03%US$381.94+0.63%
Vanguard S&P 500 ETFVOO1.5億0.01%1.8兆 USD0.03%US$715.59+0.61%
Vanguard Morningstar Small-Cap ETFVB1.3億0.07%1853億 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR8255.82萬0.12%682億 USD0.05%US$234.43+0.22%
iShares Core S&P 500 ETFIVV7962.86萬0.01%8964.4億 USD0.03%US$781.97+0.60%
State Street SPDR S&P 500 ETFSPY7311.49萬0.01%8172億 USD0.09%US$778.57+0.60%
State Street SPDR S&P 500 ETF1557.T
Invesco S&P 500 Equal Weight ETFRSP
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Value ETFVBR
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPYAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。